In 1998, I was diagnosed with metastatic melanoma and given months to live. I consulted more than a dozen leading oncologists and got conflicting recommendations. No one could tell me: ‘Which treatment is best for me?’

A clinical trial saved my life—despite itself being unsuccessful—only raising more questions. Why did this therapy work for me but not for others? Could my experience help similar patients? It was life-saving knowledge I wanted to share with all cancer patients.

Welcome to Cancer Commons.

Marty Tenenbaum, PhD Founder of Cancer Commons

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

  • Emma has been wonderful. She has been in touch regularly.

    Elise
    Ovarian cancer patient

  • Glioblastoma is devastating, and Cancer Commons made excellent recommendations to present to our medical team. They know what they are doing and have the experts that can sift through the voluminous mountain of research.

    Glory Cochrane
    Wife of glioblastoma patient

  • I was completely lost looking at trials. I didn’t know what the terms meant or where to start looking. When I received the call from the specialist, he explained (much better than our oncologist) all of our choices and the order he would start looking at trials. It gave me so much insight.

    Amanda
    Wife of a glioblastoma patient
  • In a field as complex and dynamic as molecular oncology in 2020, Cancer Commons offers an amazing opportunity for patients with advanced cancer to obtain scientifically up-to-date additional options that may improve both the length and quality of their lives, all free of charge.

    Gavin Gordon, PhD
    Molecular Pathologist

  • Sincere thanks to Cancer Commons and their Virtual Tumor Board for their comprehensive analysis and recommendations regarding treatments for my pancreatic cancer. I feel fortunate to have the benefit of the expertise offered by their board of scientists, researchers, physicians, and experts in this field.

    Roy Saenz

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.